news-releases

Latest News

  • TapImmune to Present at the 3rd Annual Growth Capi...

    JACKSONVILLE, FL, April 28, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines...

    Read more

  • TapImmune Announces Phase 2 Ovarian Cancer Trial S...

    JACKSONVILLE, Florida, April 21, 2016 /PRNewswire/ – Study to commence Q2 2016 at Sloan Kettering Institute Cancer vaccine and checkpoint inhibitor combination to be evaluated in...

    Read more

  • TapImmune Completes GMP Manufacturing and Release ...

    Doses for use at Mayo Clinic and other clinical sites Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial TapImmune, Inc. (TPIV), a clinical-stage...

    Read more

  • Join TapImmune at Jacksonville’s Immunothera...

    UPCOMING EVENT Jacksonville’s Immunotherapy Development Program The BioFlorida Northeast Chapter – Jacksonville has put together a program at Mayo Clinic focusing on the partnership...

    Read more

  • Experts say research shows promise for a breast ca...

    03/31/16 Medicine By Kathleen McGrory, Times staff writer There are vaccines to help the body fight off measles, mumps and the flu. But breast cancer? That’s exactly the technology a...

    Read more

  • Update with TapImmune, Inc. – Discusses Targ...

    LOS ANGELES, CA–(Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D.,...

    Read more

  • StockNewsNow.com Publishes New SNNLive Video Inter...

    LOS ANGELES, CA–(Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D.,...

    Read more

  • StockNewsNow.com Publishes New SNNLive Video Inter...

      LOS ANGELES, CA–(Posted on Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn...

    Read more

  • TapImmune to Present at 28th Annual ROTH Conferenc...

      JACKSONVILLE, FLORIDA, March 14, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based...

    Read more

  • TapImmune Inc (OTCMKTS:TPIV) Tapping Into Big Thin...

    TapImmune Inc (OTCMKTS:TPIV) has emerged as one of the most exciting names on the OTC markets. TPIV is on the verge of some huge developments in the biotech space. We think 2016 could be...

    Read more

  • TapImmune Receives Notice of Allowance on U.S. Pat...

    Proprietary DNA Expression Vector Technology Developed at TapImmune’s Laboratories PolyStart to Move into Clinical Trials and Expand TapImmune‘s Development Pipeline TapImmune, Inc....

    Read more

  • TapImmune Inc. gets fast track status from FDA for...

    TapImmune Inc., a Jacksonville-based immunotherapy company, has received fast track status from the U.S. Food & Drug Administration to study the use of its vaccine TPIV 200 to treat a certain...

    Read more

  • TapImmune Sponsors 26.2 With DONNA Marathon for Br...

      Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016   JACKSONVILLE, FLORIDA, February 10, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology...

    Read more

  • TapImmune: Proud Supporter of World Cancer Day, F...

    World Cancer Day is marked on February 4 to raise awareness of cancer and to encourage its prevention, detection, and treatment. World Cancer Day was founded by the Union for International Cancer...

    Read more

  • TapImmune Granted Fast Track Designation by U.S. F...

    TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &...

    Read more

  • TapImmune Appoints Frederick G. Wasserman to its B...

    TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of...

    Read more

  • TapImmune to Present at Biotech Showcase 2016 in S...

    JACKSONVILLE, FLORIDA, January 7 , 2015 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and...

    Read more

  • TapImmune moves forward with new drugs...

    By Mark Basch, Contributing Writer TapImmune Inc. is a pharmaceutical research company that may never make a big splash in Jacksonville, as far as local employment and operations go.However, the...

    Read more

  • We Are Back!

    We regret that due to circumstances beyond our control our website was offline over the weekend and yesterday.    We are in the process of re-engineering and updating our website to better serve...

    Read more

  • Patrick Yeramian Multi-Epitope Vaccine Granted Orp...

    The orphan designation for TPIV 200 was based on findings from a phase I study, which were electronically published in conjunction with the 2015 ASCO Annual Meeting. In the study, treatment with the...

    Read more

23 Nov 2015

TapImmune CEO, Glynn Wilson speaks with CBS 12′s Lynda Figueredo

Trials underway to test vaccine against several cancers Story by Lynda Figueredo/CBS12 For the first time ever, a Palm Beach County doctor is on the verge of one of the biggest medical breakthroughs of the century. The statewide clinical trials are for a vaccine that prevents breast, ovarian and...

more >

5 Nov 2015

Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida

Clinical-Stage Developer of Vaccines for Cancer & Metastatic Disease moves into closer proximity to collaborators at Mayo Clinic in Jacksonville JACKSONVILLE, Florida, November 5, 2015 /PRNewswire/ – TapImmune Inc., (TPIV) a clinical-stage immune-oncology company specializing in the...

more >

13 Oct 2015

TapImmune to Present at Dawson James Small Cap Growth Conference in Florida on October 15, 2015

JACKSONVILLE, Florida, October 13, 2015 /PRNewswire TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be a featured...

more >

7 Oct 2015

TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015

JACKSONVILLE, Florida, October 7, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a...

more >

28 Sep 2015

SeeThruEquity Issues Company Update on TapImmune Highlighting Clinical Program Updates and Recent Financing

NEW YORK, NY / ACCESSWIRE / September 28, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (TPIV). The note is available here: TPIV Update...

more >

15 Sep 2015

TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer

Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization TapImmune, Inc. (TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280...

more >

12 Sep 2015

TapImmune Director to Represent Great Britain In Triathlon World Championships

TapImmune congratulates Director David Lasko-Pooley on being selected to represent Great Britain in the “2015 ITU World Triathlon Grand Final and World Championships to be held in Chicago, IL, starting on September 15, 2015.   This event is also part of qualification for some countries for the...

more >

18 Aug 2015

TapImmune Completes Transfer of IND From The Mayo Clinic

Significant Milestone Marks The Next Major Step in Beginning Phase 2 Trials in Cancer Using The Folate Receptor Alpha Peptide Vaccine Technology SEATTLE, Wash., Aug. 18, 2015 /PRNewswire/ –TapImmune, Inc. (TPIV),  a clinical stage immunotherapy company, specializing in the development of...

more >

23 Jun 2015

TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients

Phase I Trial analyses shows safety and positive immune response data SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in...

more >

Page 1 of 212